Estrogen receptor beta in cancer: An attractive target for therapy

Current Pharmaceutical Design

Volumn 18, Issue 19, 2012, Pages 2734-2757

  Gallo, Daniela ^a   de Stefano, Ilaria ^a   Prisco, Maria Grazia ^a   Scambia, Giovanni ^a   Ferrandina, Gabriella ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Brain; Breast; Colon; ER ; Estrogen; Lung; Ovary; Prostate; Skin; Uterus; Vulva

Indexed keywords

AFIMOXIFENE; ALDOXIME; ANTIESTROGEN; ARZOXIFENE; BENZOFURAN DERIVATIVE; BENZOPYRAN DERIVATIVE; BENZOTHIOPHENE DERIVATIVE; BENZOXAZINE DERIVATIVE; BENZOXEPIN DERIVATIVE; CHROMENE DERIVATIVE; DIARYLPROPIONITRILE; DIPHENYLAMINE DERIVATIVE; ESTRADIOL DERIVATIVE; ESTROGEN; ESTROGEN RECEPTOR BETA; FURAN DERIVATIVE; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; INDENE DERIVATIVE; INDOLE DERIVATIVE; ISOCOUMARIN DERIVATIVE; LETROZOLE; PHTHALIMIDE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; RALOXIFENE; TAMOXIFEN; TETRALIN DERIVATIVE; TRIAZOLE DERIVATIVE; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BRAIN CANCER; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CHEMOSENSITIVITY; COLORECTAL CANCER; DRUG EFFICACY; DRUG POTENCY; ENDOMETRIUM CANCER; ESTROGEN THERAPY; GENE EXPRESSION REGULATION; HORMONE RECEPTOR INTERACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; TESTIS CANCER; TISSUE DISTRIBUTION; TRANSCRIPTION INITIATION;

EID: 84862570659     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212800626139     Document Type: Review

References (323)

1. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med 2002; 346: 340-52. Review.
2. Gosden JR, Middleton PG, Rout D. Localization of the human oestrogen receptor gene to chromosome 6q24-q27 by in situ hybridization. Cytogenet Cell Genet 1986; 43: 218-20.
3. Enmark E, Pelto-Huikko M, Grandien K, et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997; 82: 4258-65.
4. Walter P, Green S, Greene G, et al. Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci 1985; 82: 7889-93.
5. Green S, Walter P, Kumar V, et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986; 320: 134-9.
6. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925-30.
7. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392: 49-53.
8. Tremblay GB, Tremblay A, Copeland NG, et al. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol Endocrinol 1997; 11: 353-65.
9. Kuiper GGJM, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor b. Endocrinology 1998; 139: 4252-63.
10. Tora L, White J, Brou C, et al. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell. 1989; 59: 477-87.
11. Pace P, Taylor J, Suntharalingam S, Coombes RC, Ali S. Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha. J Biol Chem 1997; 272: 25832-8.
12. Delaunay F, Pettersson K, Tujague M, Gustafsson JA. Functional differences between the amino-terminal domains of estrogen receptors alpha and beta. Mol Pharmacol 2000; 58: 584-90.
13. Nilsson S, Mäkelä S, Treuter E, et al. Mechanisms of estrogen action. Physiol Rev 2001; 81: 1535-65. Review.
14. Moore JT, McKee DD, Slentz-Kesler K, et al. Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 1998; 247: 75-8.
15. Ogawa S, Inoue S, Watanabe T, et al. Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in human. Nucleic Acids Res 1998; 26: 3505-12.
16. Leung YK, Mak P, Hassan S, Ho SM. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci USA 2006; 103: 13162-7.
17. Suzuki T, Sasano H, Kimura N, et al. Immunohistochemical distribution of progesterone, androgen and oestrogen receptors in the human ovary during the menstrual cycle: relationship to expression of steroid enzymes. Hum Reprod 1994; 9: 1589-95.
18. Vidal O, Kindblom LG and Ohlsson C. Expression and localization of estrogen receptor-beta in murine and human bone, J Bone Miner Res 1999; 14: 923-9.
19. Saunders PT, Millar MR, Williams K, et al. Differential expression of estrogen receptor-alpha and -beta and androgen receptor in the ovaries of marmosets and humans. Biol Reprod 2000; 63: 1098-105.
20. Taylor AH, Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol 2000; 24: 145-55.
21. Anwar A, McTernan PG, Anderson LA, et al. Site-specific regulation of oestrogen receptor-alpha and -beta by oestradiol in human adipose tissue. Diabetes Obes Metab 2001; 3: 338-49.
22. Braidman IP, Hainey L, Batra G, Selby PL, Saunders PT and Hoyland JA. Localization of estrogen receptor beta protein expression in adult human bone. J Bone Miner Res 2001; 16: 214-20.
23. Thornton MJ, Taylor AH, Mulligan K, et al. Oestrogen receptor beta is the predominant oestrogen receptor in human scalp skin. Exp. Dermatol 2003; 12: 181-90.
24. Thornton MJ, Taylor AH, Mulligan K, et al. The distribution of estrogen receptor beta is distinct to that of estrogen receptor alpha and the androgen receptor in human skin and the pilosebaceous unit. J Investig Dermatol Symp Proc 2003; 8: 100-3.
25. Weiser MJ, Foradori CD, Handa RJ. Estrogen receptor beta in the brain: from form to function. Brain Res Rev 2008; 57: 309-20.
26. Khetawat G, Faraday N, Nealen ML, et al. Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): Testosterone regulates AR expression. Blood 2000; 95: 2289-96.
27. Välimaa H, Savolainen S, Soukka T, et al. Estrogen receptor-beta is the predominant estrogen receptor subtype in human oral epithelium and salivary glands. J Endocrinol 2004; 180: 55-62.
28. Ascenzi P, Bocedi A, Marino M. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med 2006; 27: 299-402.
29. Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ER-beta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999; 140: 5566-78.
30. Pettersson K, Delaunay F, Gustafsson JA. Estrogen receptor beta acts as a dominant regulator of estrogen signaling. Oncogene 2000; 19: 4970-8.
31. Ray A, Prefontaine KE, Ray P. Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J Biol Chem 1994; 269: 12940-6.
32. Galien R, Garcia T. Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. Nucleic Acids Res 1997; 25: 2424-9.
33. Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptors ER and ERß at AP1 sites. Science 1997; 277: 1508-10.
34. Porter W, Saville B, Hoivik D, Safe S. Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol 1997; 11: 1569-80.
35. Kushner PJ, Agard DA, Greene GL, et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 2000; 74: 311-7.
36. O'Lone R, Frith MC, Karlsson EK, Hansen U.Genomic targets of nuclear estrogen receptors. Mol Endocrinol 2004; 18: 1859-75.
37. Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen receptor beta: an overview and update. Nucl Recept Signal 2008 Feb 1; 6: e003. Review.
38. Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995; 270: 1491-4.
39. Coutts AS, Murphy LC. Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res 1998; 58: 4071-4.
40. Shim WS, Conaway M, Masamura S, et al. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 2000; 141: 396-405.
41. Morley P, Whitfield JF, Vanderhyden BC, Tsang BK, Schwartz JL. A new, nongenomic estrogen action: the rapid release of intracellular calcium. Endocrinology 1992; 131: 1305-12.
42. Caulin-Glaser T, Garcia-Cardena G, Sarrel P, Sessa WC, Bender JR. 17b-Estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. Circ Res 1997; 81: 885-92.
43. Levin ER. Cell localization, physiology, and nongenomic actions of estrogen receptors. J Appl Physiol 2001; 91: 1860-7.
44. Levin ER. Cellular functions of plasma membrane estrogen receptors. Steroids 2002; 67: 471-5.
45. Razandi M, Pedram A, Park ST, Levin ER. Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 2003; 278: 2701-12.
46. Razandi M, Pedram A, Greene GL, Levin ER. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERa and ERb expressed in Chinese hamster ovary cells. Mol Endocrinol 1999; 13: 307-19.
47. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000; 407; 538-41.
48. Toran-Allerand CD, Guan X, MacLusky NJ, et al. ER-X: a novel, plasma membrane-associated, putative estrogen receptor that is regulated during development and after ischemic brain injury. J Neurosci 2002; 22: 8391-401.
49. Li L, Haynes MP, Bender JR. Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc Natl Acad Sci USA 2003; 100: 4807-12.
50. Björnström L, Sjöberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 2005; 19: 833-42. Review.
51. Carmeci C, Thompson DA, Ring HZ, Francke U, Weigel, RJ. Identification of a gene (GPR30) with homology to the G-proteincoupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 1997; 45: 607-17.
52. Prossnitz ER, Arterburn JB, Sklar LA. GPR30: A G proteincoupled receptor for estrogen. Mol Cell Endocrinol 2007; 265-266: 138-42.
53. Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol 2010; 204: 105-14. Review.
54. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr. Estrogen-induced activation of Erk-1 and Erk-2 requires the G proteincoupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 2000; 14: 1649-60.
55. Filardo EJ, Quinn JA, Frackelton AR Jr, Bland KI. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 2002; 16: 70-84.
56. Kanda N, Watanabe S. 17beta-estradiol inhibits oxidative stressinduced apoptosis in keratinocytes by promoting Bcl-2 expression. J Invest Dermatol 2003; 121: 1500-9.
57. Kanda N, Watanabe S. 17beta-estradiol stimulates the growth of human keratinocytes by inducing cyclin D2 expression. J Invest Dermatol 2004; 123: 319-28.
58. Vivacqua A, Bonofiglio D, Albanito L, et al. 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30. Mol Pharmacol 2006; 70: 1414-23.
59. Vivacqua A, Bonofiglio D, Recchia AG, et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 2006; 20: 631-46.
60. Albanito L, Madeo A, Lappano R, et al. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 2007; 67: 1859-66.
61. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
62. Collins F, MacPherson S, Brown P, et al. Expression of oestrogen receptors, ERalpha, ERbeta, and ERbeta variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERalpha. BMC Cancer 2009; Sep 16; 9: 330.
63. IARC. Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon: International Agency for Research on Cancer; 2007
64. Speroff L. Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought. Menopause 2008; 15: 393-400. Review.
65. Dietel M. Hormone replacement therapy (HRT), breast cancer and tumor pathology. Maturitas 2010; 65: 183-9. Review.
66. Pelucchi C, Levi F, La Vecchia C. The rise and fall in menopausal hormone therapy and breast cancer incidence. Breast 2010; 19: 198-201.
67. Jefcoate CR, Liehr JG, Santen RJ, et al. Tissue-specific synthesis and oxidative metabolism of estrogens. In: Estrogens as endogenous carcinogens in the breast and prostate. Journal of the National Cancer Institute monograph. No. 27. Bethesda, Md.: National Cancer Institute, July 2000: 95-112.
68. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006; 354: 270-82.
69. Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 2003; 21: 28-34.
70. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339: 1609-18.
71. Baum M. Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial. Cancer Control 2004; 11: 217-21.
72. Saji S, Hirose M, Toi M. Clinical significance of estrogen receptor beta in breast cancer. Cancer Chemother Pharmacol. 2005; 56; Suppl 1: 21-6.
73. Murphy LC, Watson PH. Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer? Endocr Relat Cancer 2006; 13: 327-34.
74. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004; 64: 423-8.
75. Strom A, Hartman J, Foster JS, et al. Estrogen receptor inhibits 17 -estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 2004; 101: 1566-71.
76. Behrens D, Gill JH, Fichtner I. Loss of tumourigenicity of stably ERbeta-transfected MCF-7 breast cancer cells. Mol Cell Endocrinol 2007; 274: 19-29.
77. Hartman J, Lindberg K, Morani A, Inzunza J, Ström A, Gustafsson JA. Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 2006; 66: 11207-13.
78. Cowley SM, Hoare S, Mosselman S, Parker MG. Estrogen receptors alpha and beta form heterodimers on DNA. J Biol Chem 1997; 272: 19858-62.
79. Hayashi SI, Eguchi H, Tanimoto K, et al. The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr Relat Cancer 2003; 10: 193-202.
80. Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y, Hayashi S. Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene 2003; 22: 5011-20.
81. Fox EM, Davis RJ, Shupnik MA. ERbeta in breast canceronlooker, passive player, or active protector? Steroids 2008; 73: 1039-51. Review.
82. Williams C, Edvardsson K, Lewandowski SA, Ström A, Gustafsson JA. A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene 2008; 27: 1019-32.
83. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001; 142: 4120-30.
84. Tonetti D, Rubenstein R, Deleon M, et al. Stable transfection of an estrogen receptor beta cDNA isofrm into MDAMB231 breast cancer cells. J Steroid Biochem Mol Biol 2003; 87: 47-55.
85. Helguero LA, Faulds MH, Gustafsson JA, Haldosén LA. Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 2005; 24: 6605-16.
86. Paruthiyil S, Cvoro A, Tagliaferri M, Cohen I, Shtivelman E, Leitman DC. Estrogen receptor causes a G2 cell cycle arrest by inhibiting CDK1 activity through the regulation of cyclin B1, GADD45A, and BTG2. Breast Cancer Res Treat. 2010 Dec 1[Epub ahead of print]
87. Murphy LC, Peng B, Lewis A, et al. Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J Mol Endocrinol 2005; 34: 553-66.
88. Hodges-Gallagher L, Valentine CD, El Bader S, Kushner PJ. Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res Treat 2008; 109: 241-50.
89. Petersen OW, Hoyer PE, and Van Deurs B. Frequency and distribution of estrogen receptor positive cells in normal, non-lactating human breast tissue. Cancer Res 1987; 47: 5748-51.
90. Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997; 57: 4987-91.
91. Leygue E, Dotzlaw H, Watson PH, Murphy LC. Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res 1998; 58: 3197-201.
92. Speirs V, Parkes AT, Kerin MJ, et al. Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer? Cancer Res 1999; 59: 525-8.
93. Iwao K, Miyoshi Y, Egawa C, Ikeda N, Tsukamoto F, Noguchi S. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction. Cancer 2000; 89: 1732-8.
94. Järvinen TA, Pelto-Huikko M, Holli K, Isola J. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 2000; 156: 29-35.
95. Jensen EV, Cheng G, Palmieri C, et al. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci USA 2001; 98: 15197-202.
96. Mann S, Laucirica R, Carlson N, et al. Estrogen receptor beta expression in invasive breast cancer. Hum Pathol 2001; 32: 113-8.
97. Omoto Y, Inoue S, Ogawa S, et al. Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Lett. 2001; 163: 207-12.
98. Roger P, Sahla ME, Mäkelä S, Gustafsson JA, Baldet P, Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 2001; 61: 2537-41.
99. Murphy LC, Leygue E, Niu Y, Snell L, Ho SM, Watson PH. Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. Br J Cancer 2002; 87: 1411-6.
100. Omoto Y, Kobayashi S, Inoue S, Ogawa S. Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur J Cancer. 2002; 38: 380-6.
101. Iwase H, Zhang Z, Omoto Y, et al. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. Cancer Chemother Pharmacol 2003; 52: S34-8.
102. Park BW, Kim KS, Heo MK, et al. Expression of estrogen receptor-beta in normal mammary and tumor tissues: is it protective in breast carcinogenesis? Breast Cancer Res Treat 2003; 80: 79-85.
103. Skliris GP, Munot K, Bell SM, et al. Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 2003; 201: 213-20.
104. Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, et al. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 2004; 10: 5769-76.
105. Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 2004; 10: 7490-9.
106. Nakopoulou L, Lazaris AC, Panayotopoulou EG, et al. The favourable prognostic value of oestrogen receptor beta immunohisto-chemical expression in breast cancer. J Clin Pathol 2004; 57: 523-8.
107. O'Neill PA, Davies MP, Shaaban AM, et al. Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers. Br J Cancer 2004; 91: 1694-702.
108. Palmieri C, Lam EW, Mansi J, et al. The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res 2004; 10: 2421-8.
109. Esslimani-Sahla M, Kramar A, Simony-Lafontaine J, Warner M, Gustafsson JA, Rochefort H. Increased estrogen receptor betacx expression during mammary carcinogenesis. Clin Cancer Res 2005; 11: 3170-4.
110. Park BW, Kim KS, Heo MK, et al. The changes of estrogen receptor-beta variants expression in breast carcinogenesis: Decrease of estrogen receptor-beta2 expression is the key event in breast cancer development. J Surg Oncol 2006; 93: 504-10.
111. Skliris GP, Leygue E, Curtis-Snell L, Watson PH, Murphy LC. Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer 2006; 95: 616-26.
112. Gruvberger-Saal SK, Bendahl PO, Saal LH, et al. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res 2007; 13: 1987-94.
113. Vinayagam R, Sibson DR, Holcombe C, Aachi V, Davies MP. Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer--a retrospective study. BMC Cancer 2007; 7: 131. http://www.biomedcentral.com/1471-2407/7/131.
114. Honma N, Horii R, Iwase T, et al. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 2008; 26: 3727-34.
115. Novelli F, Milella M, Melucci E, et al. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res 2008; 10: R74.
116. Shaaban AM, Green AR, Karthik S, et al. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 2008; 14: 5228-35.
117. Hamilton-Burke W, Coleman L, Cummings M, et al. Phosphorylation of estrogen receptor beta at serine 105 is associated with good prognosis in breast cancer. Am J Pathol 2010; 177: 1079-86.
118. Motomura K, Ishitobi M, Komoike Y, et al. Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors. Oncology 2010; 79: 55-61.
119. Sugiura H, Toyama T, Hara Y, et al. Expression of estrogen receptor beta wild-type and its variant ERbetacx/beta2 is correlated with better prognosis in breast cancer. Jpn J Clin Oncol 2007; 37: 820-8.
120. Fleming FJ, Hill AD, McDermott EW, O'Higgins NJ, Young LS. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by betaestradiol and 4-hydroxytamoxifen in human breast cancer. Clin Endocrinol Metab 2004; 89: 375-83.
121. Davies MP, O'Neill PA, Innes H, et al. Correlation of mRNA for oestrogen receptor beta splice variants ERbeta1, ERbeta2/ERbetacx and ERbeta5 with outcome in endocrine-treated breast cancer. J Mol Endocrinol 2004; 33: 773-82.
122. Yan M, Rayoo M, Takano EA; kConFab Investigators, Fox SB. Nuclear and cytoplasmic expressions of ERbeta1 and ERbeta2 are predictive of response to therapy and alters prognosis in familial breast cancers. Breast Cancer Res Treat 2011; 126: 395-405.
123. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, American Cancer Society 2010.
124. Ellem SJ, Risbridger GP. The dual, opposing roles of estrogen in the prostate. Ann N Y Acad Sci 2009; 1155: 174-86. Review.
125. Ellem SJ, Risbridger GP. Treating prostate cancer: a rationale for targeting local oestrogens. Nat Rev Cancer 2007; 7: 621-7.
126. Carruba G, Pfeffer U, Fecarotta E, et al. Estradiol inhibits growth of hormone-nonresponsive PC3 human prostate cancer cells. Cancer Res 1994; 54: 1190-3.
127. Castagnetta L, Miceli MD, Sorci C, et al. Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor. Endocrinology 1995; 136: 2309-19.
128. Arnold JT, Le H., McFann KK, and Blackman MR. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. Am J Physiol Endocrinol Metab 2005; 288: E573-84.
129. Cheng J, Lee EJ, Madison LD, Lazennec G. Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett 2004; 566: 169-72.
130. Pravettoni A, Mornati O, Martini PG, et al. Estrogen receptor beta (ERbeta) and inhibition of prostate cancer cell proliferation: studies on the possible mechanism of action in DU145 cells. Mol Cell Endocrinol. 2007; 263: 46-54.
131. Mak P, Leav I, Pursell B, et al. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 2010; 17: 319-32.
132. Miró AM, Sastre-Serra J, Pons DG, Valle A, Roca P, Oliver J. 17 Estradiol regulates oxidative stress in prostate cancer cell lines according to ERalpha/ERbeta ratio. J Steroid Biochem Mol Biol 2011; 123: 133-9.
133. Sugiyama N, Barros RP, Warner M, Gustafsson JA. ERbeta: recent understanding of estrogen signaling. Trends Endocrinol Metab 2010; 21: 545-52. Review.
134. Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y, Risbridger GP. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. Faseb J 2008; 22: 1512-20.
135. McPherson SJ, Wang H, Jones ME, et al. Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology 2001; 142: 2458-67.
136. McPherson SJ, Ellem SJ, Simpson ER, Patchev V, Fritzemeier KH, Risbridger GP. Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia. Endocrinology 2007; 148: 566-74.
137. McPherson SJ, Hussain S, Balanathan P, et al. Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc Natl Acad Sci USA 2010; 107: 3123-8.
138. Pelletier G, El-Alfy M. Immunocytochemical localization of estrogen receptors alpha and beta in the human reproductive organs. J Clin Endocrinol Metab 2000; 85: 4835-40.
139. Leav I, Lau KM, Adams JY, et al. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 2001; 159: 79-92.
140. Royuela M, de Miguel MP, Bethencourt FR, et al. Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. J Endocrinol 2001; 168: 447-54.
141. Tsurusaki T, Aoki D, Kanetake H, et al. Zone-dependent expression of estrogen receptors alpha and beta in human benign prostatic hyperplasia. J Clin Endocrinol Metab 2003; 88: 1333-40.
142. Fujimura T, Takahashi S, Urano T, et al. Differential expression of estrogen receptor beta (ERbeta) and its C-terminal truncated splice variant ERbetacx as prognostic predictors in human prostatic cancer. Biochem Biophys Res Commun 2001; 289: 692-9.
143. Horvath LG, Henshall SM, Lee CS, et al. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res 2001; 61: 5331-5.
144. Latil A, Bièche I, Vidaud D, Lidereau R, Berthon P, Cussenot O, Vidaud M. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 2001; 61: 1919-26.
145. Fixemer T, Remberger K, Bonkhoff H. Differential expression of the estrogen receptor beta (ER beta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 2003; 54: 79-87.
146. Nanni S, Benvenuti V, Grasselli A, et al. Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest. 2009; 119: 1093-108.
147. Celhay O, Yacoub M, Irani J, Dore B, Cussenot O, Fromont G. Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression. J Urol 2010; 184: 2172-8.
148. Leung YK, Lam HM, Wu S, et al. Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr Relat Cancer 2010; 17: 675-89.
149. Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids. 2008; 73: 233-44. Review
150. Pasquali D, Staibano S, Prezioso D, et al. Estrogen receptor beta expression in human prostate tissue. Mol Cell Endocrinol. 2001; 178: 47-50.
151. Weihua Z, Warner M, Gustafsson JA. Estrogen receptor beta in the prostate. Mol Cell Endocrinol 2002; 193: 1-5. Review.
152. Carruba G. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J Cell Biochem 2007; 102: 899-911. Review.
153. Walton TJ, Li G, McCulloch TA, et al. Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue. Prostate 2009; 69: 810-9.
154. Lai JS, Brown LG, True LD, et al. Metastases of prostate cancer express estrogen receptor-beta. Urology 2004; 64: 814-20.
155. Calle EE, Miracle-Mahill HL, Thun MJ, Health CW Jr Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995; 87: 517-23.
156. Newcomb PA & Storer BE. Postmenopausal hormone use and risk of large-bowel cancer. JNCI 1995; 87: 1067-71.
157. Kampman E, Potter JD, Slattery ML, Caan BJ, Edwards S. Hormone replacement therapy, reproductive history, and colon cancer: a multi-center, case-control study in the United States. Cancer Causes and Control 1997; 8: 146-58.
158. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288: 872-81
159. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
160. Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML. Functional estrogen receptor beta in colon cancer cells. Biochem Biophys Res Commun 1999; 261: 521-7.
161. Qiu Y, Waters CE, Lewis AE, Langman MJ, Eggo MC. Oestrogeninduced apoptosis in colonocytes expressing oestrogen receptor beta. J Endocrinol 2002; 174: 369-77.
162. Hsu HH, Cheng SF, Wu CC, et al. Apoptotic effects of overexpressed estrogen receptor-beta on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner. Chin J Physiol 2006; 49: 110-16.
163. Marino M, Galluzzo P, Leone S, Acconcia F, Ascenzi P. Nitric oxide impairs the 17beta-estradiol-induced apoptosis in human colon adenocarcinoma cells. Endocr Relat Cancer 2006; 13: 559-69.
164. Caiazza F, Galluzzo P, Lorenzetti S, Marino M. 17beta-Estradiol induces ERbeta up-regulation via p38/MAPK activation in colon cancer cells. Biochem Biophys Res Commun 2007; 359: 102-07.
165. Martineti V, Picariello L, Tognarini I, et al. Erbeta is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components. Endocr Relat Cancer 2005; 12: 455-69.
166. Edvardsson K, Ström A, Jonsson P, Gustafsson JA, Williams C. Estrogen Receptor {beta} Induces Antiinflammatory and Antitumorigenic Networks in Colon Cancer Cells. Mol Endocrinol 2011; 25: 969-79.
167. Wada-Hiraike O, Imamov O, Hiraike H, et al. Role of estrogen receptor beta in colonic epithelium. Proc Natl Acad Sci USA 2006; 103: 2959-64.
168. Weige CC, Allred KF, Allred CD. Estradiol alters cell growth in nonmalignant colonocytes and reduces the formation of preneoplastic lesions in the colon. Cancer Res 2009; 69: 9118-24.
169. Weyant MJ, Carothers AM, Mahmoud NN, et al. Reciprocal expression of ERalpha and ERbeta is associated with estrogenmediated modulation of intestinal tumorigenesis. Cancer Res 2001; 61: 2547-51.
170. Giroux V, Lemay F, Bernatchez G, Robitaille Y, Carrier JC. Estrogen receptor beta deficiency enhances small intestinal tumorigenesis in ApcMin/+ mice. Int J Cancer 2008; 123: 303-11.
171. Motylewska E, Stasikowska O, Mee-Mucha G. The inhibitory effect of diarylpropionitrile, a selective agonist of estrogen receptor beta, on the growth of MC38 colon cancer line. Cancer Lett 2009; 276: 68-73.
172. Giroux V, Bernatchez G, Carrier JC. Chemopreventive effect of ER -Selective agonist on intestinal tumorigenesis in Apc(Min/+) Mice. Mol Carcinog 2011; 50: 359-69.
173. Cho JL, Allanson M, Reeve VE. Oestrogen receptor-beta signalling protects against transplanted skin tumour growth in the mouse. Photochem Photobiol Sci 2010; 9: 608-14.
174. Waliszewski P, Blaszczyk M, Wolinska-Witort E, Drews M, Snochowski M & Hurst RE Molecular study of sex steroid receptor gene expression in human colon and in colorectal carcinomas. J Surg Oncol 1997; 64: 3-11.
175. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW. Selective loss of estrogen receptor b in malignant human colon. Cancer Res 2000; 60: 245-8.
176. Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERb isoforms in colon cancer. Cancer Res 2001; 61: 632-40.
177. Witte D, Chirala M, Younes A, Li Y, Younes M. Estrogen receptor beta is expressed in human colorectal adenocarcinoma Hum Pathol 2001; 32: 940-4.
178. Konstantinopoulos PA, Kominea A, Vandoros G, et al. Oestrogen receptor beta (ERb) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation, Eur J Cancer 2003; 39: 1251-8.
179. Wong NA, Malcomson RD, Jodrell DI, Groome NP, Harrison DJ, Saunders PT. ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. J Pathol 2005; 207: 53-60.
180. Castiglione F, Taddei A, Degl'Innocenti DR, et al. Expression of estrogen beta receptors in colon cancer progression. Diagn Mol Pathol 2008; 17: 231-6.
181. Fang YJ, Lu ZH, Wang F, et al. Prognostic impact of ER and MMP7 expression on overall survival in colon cancer. Tumour Biol 2010; 31: 651-8.
182. Siegfried JM, Hershberger PA, Stabile LP. Estrogen receptor signaling in lung cancer. Semin Oncol 2009; 36: 524-31.
183. Patel JD, Bach PB, Kris MG. Lung cancer in US women: a contemporary epidemic. JAMA 2004; 291: 1763-8.
184. Taioli E, Wynder EL. Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 1994; 86: 869-70.
185. Ganti AK, Sahmoun AE, Panwalkar AW, Tendulkar KK, Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 2006; 24: 59-63.
186. Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomized controlled trial. Lancet 2009; 374: 1243-51.
187. Kreuzer M, Gerken M, Heinrich J, Kreienbrock L, Wichmann HE. Hormonal factors and risk of lung cancer among women? Int J Epidemiol 2003; 32: 263-71.
188. Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res 2004; 10: 113-23.
189. Schwartz AG, Wenzlaff AS, Prysak GM, et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol 2007; 25: 5785-92.
190. Niikawa H, Suzuki T, Miki Y, et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res 2008; 14: 4417-26.
191. Hershberger PA, Vasquez AC, Kanterewicz B, Land S, Siegfried JM, Nichols M. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res 2005; 65: 1598-605.
192. Hershberger PA, Stabile LP, Kanterewicz B, et al. Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. J Steroid Biochem Mol Biol 2009; 116: 102-9.
193. Zhang G, Liu X, Farkas AM, et al. Estrogen receptor beta functions through nongenomic mechanisms in lung cancer cells. Mol Endocrinol 2009; 23: 146-56.
194. Zhang G, Yanamala N, Lathrop KL, Zhang L, Klein-Seetharaman J, Srinivas H. Ligand-independent antiapoptotic function of estrogen receptor-beta in lung cancer cells. Mol Endocrinol 2010; 24: 1737-47.
195. Stabile LP, Davis AL, Gubish CT, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 2002; 62: 2141-50.
196. Omoto Y, Kobayashi Y, Nishida K, et al. Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun 2001; 285: 340-7.
197. Kawai H, Ishii A, Washiya K, Konno T, et al. Estrogen Receptor alfa and beta are Prognostic Factors in Non-Small Cell Lung Cancer. Clin Cancer Res 2005; 11: 5084-9.
198. Schwartz AG, Prysak GM, Murphy V, et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res 2005; 11: 7280-7.
199. Wu CT, Chang YL, Shih JY, Lee YC. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 2005; 130: 979-86.
200. Skov BG, Fischer BM, Pappot H. Oestrogen receptor over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer 2008; 59: 88-94.
201. Nose N, Sugio K, Oyama T, et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol. 2009; 27: 411-7.
202. Nose N, Uramoto H, Iwata T, Hanagiri T, Yasumoto K. Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung. Lung Cancer 2011; 71: 350-5.
203. Stabile LP, Dacic S, Land SR, et al. Combined analysis of estrogen receptor {beta}-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res 2011; 17: 154-64.
204. Raso MG, Behrens C, Herynk MH, et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 2009; 15: 5359-68.
205. Miki Y, Abe K, Suzuki S, Suzuki T, Sasano H. Suppression of estrogen actions in human lung cancer. Mol Cell Endocrinol. 2011 Feb 25[Epub ahead of print]
206. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-92.
207. Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev 2005; 14: 98-107. Review.
208. Colombo N, Van Gorp T, Parma G, et al. Ovarian cancer. Crit Rev Oncol Hematol 2006; 60: 159-79.
209. Zhou B, Sun Q, Cong R, et al. Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol 2008; 108: 641-51.
210. Gwinn ML, Lee N, Rhodes PH, Layde PM, Rubin GL. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol 1989; 43: 559-68.
211. Vessey MP, Painter R. Endometrial and ovarian cancer and oral contraceptives-findings in a large cohort study. Br J Cancer 1995; 71: 1340-2.
212. Kiley J, Hammond C. Combined oral contraceptives: a comprehensive review. Clin Obstet Gynecol 2007; 50: 868-77.
213. Bowman A, Gabra H, Langdon SP, et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 2002; 8: 2233-9.
214. Papadimitriou CA, Markaki S, Siapkaras J, et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 2004; 66: 112-7.
215. Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991; 68: 269-71.
216. Ahlgren JD, Ellison NM, Gottlieb RJ, et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 1993; 11: 195-768.
217. Makar AP. Hormone therapy in epithelial ovarian cancer. Endocr Relat Cancer 2000; 7: 85-93. Review.
218. Scambia G, Ferrandina G, D'Ablaing G, et al. Estrogen and progesterone receptors in ovarian carcinoma. Endocr Relat Cancer 1998; 5: 293-301.
219. Cunat S, Hoffmann P, Pujol P. Estrogens and epithelial ovarian cancer. Gynecol Oncol. 2004; 94: 25-32. Review.
220. O'Donnell AJ, Macleod KG, Burns DJ, Smyth JF, Langdon SP. Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr Relat Cancer 2005; 12: 851-66
221. Armaiz-Pena GN, Mangala LS, Spannuth WA, et al. Estrous cycle modulates ovarian carcinoma growth. Clin Cancer Res 2009; 15: 2971-8.
222. Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G, Ortmann O. Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol 2007; 193: 421-33.
223. Suzuki F, Akahira J, Miura I, et al. Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma. Cancer Sci 2008; 99: 2365-72.
224. Lindgren PR, Cajander S, Bäckström T, Gustafsson JA, Mäkelä S, Olofsson JI. Estrogen and progesterone receptors in ovarian epithelial tumors. Mol Cell Endocrinol 2004; 221: 97-104.
225. Chan KK, Wei N, Liu SS, Xiao-Yun L, Cheung AN, Ngan HY. Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Obstet Gynecol 2008; 111: 144-51.
226. Burges A, Brüning A, Dannenmann C, et al. Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary. Arch Gynecol Obstet 2010; 281: 511-7.
227. Brandenberger AW, Tee MK, Jaffe RB. Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: downregulation of ER-beta in neoplastic tissues. J Clin Endocrinol Metab 1998; 83: 1025-8.
228. Pujol P, Rey JM, Nirde P, et al. Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 1998; 58: 5367-73.
229. Lazennec G. Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis. Cancer Lett 2006; 231: 151-7.
230. Drummond AE, Fuller PJ. The importance of ER beta signalling in the ovary. J Endocrinol 2010; 205: 15-23.
231. Halon A, Nowak-Markwitz E, Maciejczyk A, et al. Loss of estrogen receptor Beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients. Anticancer Res 2011; 31: 711-8.
232. De Stefano I, Zannoni GF, Prisco MG, et al. Cytoplasmic expression of Estrogen Receptor beta (ER) predicts poor clinical outcome in advanced serous ovarian cancer. Gynecol Oncol 2011; 122: 573-9.
233. Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W. Hormonal interactions in endometrial cancer. Endocr Relat Cancer 2000; 7: 227-42.
234. Chaudhry P, Asselin E. Resistance to chemotherapy and hormone therapy in endometrial cancer. Endocr Relat Cancer 2009; 16: 363-80.
235. Steed HL, Chu QS. Aromatase inhibition: a potential target for the management of recurrent or metastatic endometrial cancer by letrozole: more questions than answers? Expert Opin Investig Drugs 2011; 20: 681-90.
236. Holinka CF, Hata H, Gravanis A, Kuramoto H, Gurpide E. Effects of estradiol on proliferation of endometrial adenocarcinoma cells (Ishikawa line). J Steroid Biochem 1986; 25: 781-6.
237. Dardes RC, Schafer JM, Pearce ST, Osipo C, Chen B, Jordan VC. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells. Gynecol Oncol 2002; 85: 498-506.
238. Barrett I, Meegan MJ, Hughes RB, et al. Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators. Bioorg Med Chem 2008; 16: 9554-73.
239. Weihua Z, Saji S, Makinen S, et al. Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus. Proc Natl Acad Sci USA 2000; 97: 5936-41.
240. Mylonas I, Makovitzky J, Friese K, Jeschke U. Immunohistochemical labelling of steroid receptors in normal and malignant human endometrium. Acta Histochem 2009; 111: 349-59.
241. Critchley HO, Henderson TA, Kelly RW, et al. Wild-type estrogen receptor (ERbeta1) and the splice variant (ERbetacx/beta2) are both expressed within the human endometrium throughout the normal menstrual cycle. J Clin Endocrinol Metab 2002; 87: 5265-73.
242. Jazaeri AA, Nunes KJ, Dalton MS, Xu M, Shupnik MA, Rice LW. Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. Oncogene 2001; 20: 6965-9.
243. Fujimoto J, Sakaguchi H, Aoki I, Toyoki H, Tamaya T. Clinical implications of the expression of estrogen receptor-alpha and -beta in primary and metastatic lesions of uterine endometrial cancers. Oncology 2002; 62: 269-77.
244. Skrzypczak M, Bieche I, Szymczak S, et al. Evaluation of mRNA expression of estrogen receptor beta and its isoforms in human normal and neoplastic endometrium. Int J Cancer 2004; 110: 783-7.
245. Chakravarty D, Srinivasan R, Ghosh S, Gopalan S, Rajwanshi A, Majumdar S. Estrogen receptor beta1 and the beta2/betacx isoforms in nonneoplastic endometrium and in endometrioid carcinoma. Int J Gynecol Cancer 2007; 17: 905-13.
246. Collins JA, Blake JM, Crosignani PG. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 2005; 11: 545-60.
247. Takama F, Kanuma T, Wang D, Kagami I, Mizunuma H. Oestrogen receptor beta expression and depth of myometrial invasion in human endometrial cancer. Br J Cancer 2001; 84: 545-9.
248. Chakravarty D, Gupta N, Goda JS, Srinivasan R, Patel FD, Dhaliwal L. Steroid receptors, HER2/neu and Ki-67, in endometrioid type of endometrial carcinoma: Correlation with conventional histomorphological features of prognosis. Acta Histochem 2010; 112: 355-63.
249. Shabani N, Kuhn C, Kunze S, et al. Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer 2007; 43: 2434-44.
250. Jongen V, Briët J, de Jong R, et al. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol 2009; 112: 537-42.
251. Thornton,M.J. The biological actions of estrogens on skin. Exp Dermatol 2002; 11: 487-502.
252. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010; 146: 283-7.
253. Oberyszyn TM. Non-melanoma skin cancer: importance of gender, immunosuppressive status and vitamin D. Cancer Lett 2008; 261: 127-36.
254. Lupulescu A. Hormonal regulation of epidermal tumor development. J Invest Dermatol 1981; 77: 186-95.
255. Mancuso M, Gallo D, Leonardi S, et al. Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer. Carcinogenesis 2009; 30: 340-7.
256. Cho NL, Javid SH, Carothers AM, Redston M, Bertagnolli MM. Estrogen receptors alpha and beta are inhibitory modifiers of Apcdependent tumorigenesis in the proximal colon of Min/+ mice. Cancer Res 2007; 67: 2366-72.
257. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-34.
258. de Vries E, Nijsten TE, Visser O, et al. Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol 2008; 19: 583-9.
259. Driscoll MS, Grant-Kels JM. Hormones, nevi, and melanoma: an approach to the patient. J Am Acad Dermatol 2007; 57: 919-31.
260. Lens M, Bataille V. Melanoma in relation to reproductive and hormonal factors in women: current review on controversial issues. Cancer Causes Control 2008; 19: 437-42.
261. Koomen ER, Joosse A, Herings RM, Casparie MK, Guchelaar HJ, Nijsten T. Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study. Ann Oncol 2009; 20: 358-64.
262. Feucht KA, Walker MJ, Das Gupta TK, Beattie CW. Effect of 17 beta-estradiol on the growth of estrogen receptor-positive human melanoma in vitro and in athymic mice. Cancer Res 1988; 48: 7093-101.
263. Richardson B, Price A, Wagner M, et al. Investigation of female survival benefit in metastatic melanoma. Br J Cancer 1999; 80: 2025-33.
264. Kanda N, Watanabe S. 17beta-estradiol, progesterone, and dihydrotestosterone suppress the growth of human melanoma by inhibiting interleukin-8 production. J Invest Dermatol. 2001; 117: 274-83.
265. Schmidt AN, Nanney LB, Boyd AS, King LE Jr, Ellis DL. Oestrogen receptor-beta expression in melanocytic lesions. Exp Dermatol 2006; 15: 971-80.
266. de Giorgi V, Mavilia C, Massi D, et al. Estrogen receptor expression in cutaneous melanoma: a real-time reverse transcriptasepolymerase chain reaction and immunohistochemical study. Arch Dermatol 2009; 145: 30-6.
267. Horner MJ, Ries LAG, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009.
268. Stroup AM, Harlan LC, Trimble EL. Demographic, clinical, and treatment trends among women diagnosed with vulvar cancer in the United States. Gynecol Oncol 2008; 108: 577-83.
269. Taylor AH, Guzail M, Al-Azzawi F. Differential expression of oestrogen receptor isoforms and androgen receptor in the normal vulva and vagina compared with vulval lichen sclerosus and chronic vaginitis. Br J Dermatol 2008; 158: 319-28.
270. Zannoni GF, Prisco Mg, Vellone VG, et al. Changes in the expression of Oestrogen Receptors and E-cadherin as molecular markers of progression from normal epithelium to invasive cancer in elderly patients with vulvar squamous cell carcinoma: a pilot study. Histopathology 2011; 58: 265-75.
271. Zannoni GF, Prisco MG, Vellone VG, et al. Cytoplasmic expression of Estrogen Receptor beta (ER) as a prognostic factor in vulvar squamous cell carcinoma in elderly women. Histopathology 2011; 59: 909-17.
272. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50.
273. Levin VA, Leibel SA, Gutin PH. Neoplasms of the central nervous system. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2001: 2100-60.
274. Preston-Martin S, Staples M, Farrugia H, Giles G. Primary tumors of the brain, cranial nerves and cranial meninges in Victoria. Australia, 1982-1990: patterns of incidence and survival. Neuroepidemiology 1993; 12: 270-9.
275. Prados MD, Warnick RE, Wara WM, Larson DA, Lamborn K, Wilson CB. Medulloblastoma in adults. Int J Radiat Oncol Biol Phys 1995; 32: 1145-52.
276. Weil MD, Lamborn K, Edwards MS, Wara WM. Influence of a child's sex on medulloblastoma outcome. JAMA 1998; 279: 1474-6.
277. Gurney JG, Kadan-Lottick N. Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr Opin Oncol 2001; 13: 160-6.
278. Huang K, Whelan EA, Ruder AM, et al. Reproductive factors and risk of glioma in women. Cancer Epidemiol Biomarkers Prev 2004; 13: 1583-8.
279. Hatch EE, Linet MS, Zhang J, et al. Reproductive and hormonal factors and risk of brain tumors in adult females. Int J Cancer 2005; 114: 797-805.
280. Silvera SA, Miller AB, Rohan TE. Hormonal and reproductive factors and risk of glioma: a prospective cohort study. Int J Cancer. 2006; 118: 1321-4.
281. Wigertz A, Lönn S, Mathiesen T, Ahlbom A, Hall P, Feychting M; Swedish Interphone Study Group. Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol. 2006; 164: 629-36.
282. Claus EB, Black PM, Bondy ML, Calvocoressi L, Schildkraut JM, Wiemels JL, Wrensch M. Exogenous hormone use and meningioma risk: what do we tell our patients? Cancer 2007; 110: 471-6.
283. Curran EK, Sainani KL, Le GM, Propp JM, Fisher PG. Gender affects survival for medulloblastoma only in older children and adults: a study from the Surveillance Epidemiology and End Results Registry. Pediatr Blood Cancer 2009; 52: 60-4.
284. Huppmann AR, Orenstein JM, Jones RV. Cerebellar medulloblastoma in the elderly. Ann Diagn Pathol 2009; 13: 55-9.
285. Benson VS, Pirie K, Green J, et al. Million Women Study Collaborators. Hormone replacement therapy and incidence of central nervous system tumours in the Million Women Study. Int J Cancer 2010; 127: 1692-8.
286. Belcher SM, Ma X, Le HH. Blockade of estrogen receptor signaling inhibits growth and migration of medulloblastoma. Endocrinology 2009; 150: 1112-21.
287. Mancuso M, Leonardi S, Ceccarelli M, et al. Protective role of 17beta-estradiol on medulloblastoma development in Patched1 heterozygous mice. Int J Cancer 2010; 127, 2749-57.
288. Mancuso M, Leonardi S, Giardullo P, et al. The estrogen receptor beta agonist diarylpropionitrile (DPN) inhibits medulloblastoma development via anti-proliferative and pro-apototic pathways. Cancer Letters. 2011; 308: 197-202.
289. Gittoes NJ, McCabe CJ, Sheppard MC, Franklyn JA. Estrogen receptor beta mRNA expression in normal and adenomatous pituitaries. Pituitary 1999; 1: 99-104.
290. Carroll RS, Zhang J, Black PM. Expression of estrogen receptors alpha and beta in human meningiomas. J Neurooncol 1999; 42: 109-16.
291. Batistatou A, Stefanou D, Goussia A, Arkoumani E, Papavassiliou AG, Agnantis NJ. Estrogen receptor beta (ERbeta) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasm. J Cancer Res Clin Oncol. 2004; 130: 405-10.
292. Urbanska K, Pannizzo P, Lassak A, et al. Estrogen receptor betamediated nuclear interaction between IRS-1 and Rad51 inhibits homologous recombination directed DNA repair in medulloblastoma. J Cell Physiol 2009; 219: 92-401.
293. Batistatou A, Kyzas PA, Goussia A, et al. Estrogen receptor beta (ERbeta) protein expression correlates with BAG-1 and prognosis in brain glial tumours. J Neurooncol 2006; 77: 17-23.
294. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents. vol. 8. Lyon: IARC, 2002. Publication no. 155.
295. Hem E, Attramadal A, and Tveter KJ. Synchronous bilateral primary germ cell tumors in patient receiving estrogen therapy. Urology 1988; 31: 70-71.
296. Olsson HL, Bladstrom A, and Alm P. Gynecomastia and risk for malignant tum. BMC Cancer 2002; 2: 26.
297. Garner MJ, Turner MC, Ghadirian P, Krewski D. Epidemiology of testicular cancer: an overview. Int J Cancer 2005; 116: 331-9.
298. Bosland MC. Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models. Prog Clin Biol Res 1996; 394: 309-52.
299. Bouskine A, Nebout M, Mograbi B, Brücker-Davis F, Roger C, Fenichel P. Estrogens promote human testicular germ cell cancer through a membrane-mediated activation of extracellular regulated kinase and protein kinase A. Endocrinology 2008; 149: 565-73.
300. Roger C, Lambard S, Bouskine A, et al. Estrogen-induced growth inhibition of human seminoma cells expressing estrogen receptor beta and aromatase. J Mol Endocrinol 2005; 35: 191-9.
301. Mäkinen S, Mäkelä S, Weihua Z, et al. Localization of oestrogen receptors alpha and beta in human testis. Mol Hum Reprod 2001; 7: 497-503.
302. Pais V, Leav I, Lau KM, Jiang Z, Ho SM. Estrogen receptor-beta expression in human testicular germ cell tumors. Clin Cancer Res. 2003; 9: 4475-82.
303. Hirvonen-Santti SJ, Rannikko A, Santti H, et al. Down-regulation of estrogen receptor beta and transcriptional coregulator SNURF/RNF4 in testicular germ cell cancer. Eur Urol 2003; 44: 742-7.
304. Rago V, Romeo F, Giordano F, Ferraro A, Andò S, Carpino A. Identification of ERbeta1 and ERbeta2 in human seminoma, in embryonal carcinoma and in their adjacent intratubular germ cell neoplasia. Reprod Biol Endocrinol 2009 Jun 3; 7: 56.
305. Meyers MJ, Sun J, Carlson KE, et al. Estrogen receptor-beta potency-selective ligands: structure-activityrelationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem 2001; 44: 4230-51.
306. Minutolo F, Macchia M, Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor ligands: Recent advances and biomedical applications. Med Res Rev. 2011; 31: 364-442.
307. Paruthiyil S, Cvoro A, Zhao X, et al. Drug and cell type-specific regulation of genes with different classes of estrogen receptor betaselective agonists. PLoS One 2009 Jul 17; 4(7): e6271.
308. Blizzard TA. Selective estrogen receptor modulator medicinal chemistry at Merck. A review.Curr Top Med Chem 2008; 8: 792-812. Review.
309. Deroo BJ, Buensuceso AV. Minireview: Estrogen receptor-beta: mechanistic insights from recent studies. Mol Endocrinol. 2010; 24: 1703-14.
310. Nilsson S, Gustafsson JÅ. Estrogen receptors: therapies targeted to receptor subtypes. Clin Pharmacol Ther 2011; 89: 44-55. Review.
311. Roman-Blas JA, Castañeda S, Cutolo M, Herrero-Beaumont G. Efficacy and safety of a selective estrogen receptor agonist, ERB-041, in patients with rheumatoid arthritis: a 12-week, randomized, placebo-controlled, phase II study. Arthritis Care Res (Hoboken). 2010; 62: 1588-93.
312. Sarkar FH, Li Y, Wang Z, Padhye S. Lesson learned from nature for the development of novel anti-cancer agents: implication of isoflavone, curcumin, and their synthetic analogs. Curr Pharm Des 2010; 16: 1801-12.
313. Vivar OI, Zhao X, Saunier EF, et al. Estrogen receptor beta binds to and regulates three distinct classes of target genes. J Biol Chem 2010; 285: 22059-66.
314. Liu MM, Albanese C, Anderson CM, et al. Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem 2002; 277: 24353-60.
315. Acconcia F, Totta P, Ogawa S, et al. Survival versus apoptotic 17beta-estradiol effect: role of ER alpha and ER beta activated non-genomic signaling. J Cell Physiol 2005; 203: 193-201.
316. Korach KS, Emmen JM, Walker VR, et al. Update on animal models developed for analyses of estrogen receptor biological activity. J Steroid Biochem Mol Biol 2003; 86: 387-91.
317. Matthews J, Gustafsson JA. Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv 2003; 3: 281-92. Review.
318. Levy N, Paruthiyil S, Zhao X, et al. Unliganded estrogen receptor-beta regulation of genes is inhibited by tamoxifen. Mol Cell Endocrinol 2010; 315: 201-7.
319. Warner M, Gustafsson JA. The role of estrogen receptor beta (ERbeta) in malignant diseases--a new potential target for antiproliferative drugs in prevention and treatment of cancer. Biochem Biophys Res Commun 2010; 396: 63-6. Review.
320. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ER-beta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 2004; 11: 537-51. Review.
321. Swedenborg E, Power KA, Cai W, Pongratz I, Rüegg J. Regulation of estrogen receptor beta activity and implications in health and disease. Cell Mol Life Sci 2009; 66: 3873-94.
322. Kelloff GJ, Lippman SM, Dannenberg AJ et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer-a plan to move forward. Clin. Cancer Res 2006; 12; 3661-97. Review.
323. Katzenellenbogen BS, Choi I, Delage-Mourroux R, et al. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J Steroid Biochem Mol Biol 2000; 74: 279-85. Review.